Stifel Remains a Buy on Artivion (AROT)

Artivion, Inc. (NYSE:AORT) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 5, Artivion, Inc. (NYSE:AORT) was reiterated with a Buy rating by analyst John McAulay of Stifel with a price target of $55. ​The analyst said in a research note that the Buy rating is based on the company’s promising aortic disease pipeline. He highlighted Artivion’s NEXUS stent graft system as the next key launch for treating chronic aortic arch dissections and aneurysms, estimating a $150 mil ...